Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab and Tacrolimus in Liver Transplantation
NCT00105235Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2005
- Primary completion
- Mar 2007
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in Liver transplant rejection, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Proportion of Participants Who Have Graft Loss or Death at 1 year. Started Jun 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT00105235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00105235.